The Oncology Institute, Inc. provides value-based community oncology care through clinics and affiliate locations across multiple states. Company updates commonly cover quarterly results, payor and Medicare Advantage contract activity, capitated care models, specialty pharmacy performance, clinical trials, transfusions, and participation in CMS oncology care programs.
News also addresses clinical pathways, legal and compliance leadership, and healthcare investor conference participation. The issuer's public securities include common stock under TOI and redeemable warrants under TOIIW.
The Oncology Institute (NASDAQ: TOI) announced its Q1 2024 financial results, reporting a 24.2% increase in consolidated revenue to $95 million. Despite this, the gross profit decreased by 15.1% to $12 million, with net losses reducing to $19.9 million from the previous year's $30 million. The net loss per share improved to $(0.22) from $(0.33). Adjusted EBITDA was $(10.9) million, higher than the $(7.4) million from the prior year. The company ended Q1 with $66 million in cash and short-term investments. Operationally, TOI signed seven new capitation and value-based contracts across three states, integrated a capitated risk contract with a health plan in Florida, and expanded its MSO model in Florida. The firm also increased the number of scripts dispensed by 70% and hired seven new providers, bringing the total to 126 employed providers across 73 clinics. CEO Daniel Virnich highlighted the company's revenue growth and new partnerships as key milestones.
The Oncology Institute, Inc. (NASDAQ: TOI) disclosed that Dr. Daniel Virnich, TOI’s CEO, will join the 'Defining the Next Chapter in Value-Based Care' panel at the Leerink Healthcare Transformation Summit on May 16, 2024. TOI is a leading value-based oncology practice in the U.S.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.